However, androgen-deprivation therapies cannot completely abolish AR signaling and most prostate cancers become eventually castration-resistant prostate cancer (CRPC), because of the occurence of AR gene point mutations or truncation [6]. This evidence concerns the gene AR and prostate cancer.